narvo vexar
Biogen (BIIB) has entered into a definitive agreement to acquire private biotechnology firm RayThera Inc. in a transaction valued at up to $1B.
The strategic acquisition focuses on expanding Biogen’s long-term pipeline footprint within the high-growth immunology and anti-inflammatory sectors.
